| Jul'19 | Jul'18 | Jul'17 | Jul'16 | Jul'15 | Jul'14 | Jul'13 | Jul'12 | Jul'11 | Jul'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities | |||||||||
Net income (loss) | |||||||||
330 | 5,199 | 9,641 | 25,358 | 86,115 | 21,010 | 13,444 | 38,785 | 23,371 | 20,273 |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||||||||
Net loss from discontinued operations | |||||||||
- | - | - | - | - | - | -4,634 | 7,851 | 2,384 | 13,701 |
Depreciation and amortization | |||||||||
22,632 | 22,801 | 21,704 | 20,535 | 18,418 | 16,318 | 14,910 | 16,648 | 20,952 | 33,341 |
Impairment of building and improvements | |||||||||
- | - | - | - | - | - | 4,359 | 0 | - | - |
Severance and other payments | |||||||||
- | - | - | - | - | - | - | - | 2,978 | 2,457 |
Deferred income taxes | |||||||||
285 | 6,174 | -2,329 | 3,809 | 5,877 | 2,487 | 15,198 | -37,925 | -2,130 | -690 |
Provision for doubtful accounts receivable | |||||||||
2,028 | 2,199 | 686 | 1,519 | 97 | 500 | 2,743 | 2,098 | 3,319 | 3,769 |
Gain on sale of interest in Fabrix Systems Ltd. | |||||||||
- | - | - | 1,086 | 76,864 | 0 | 0 | - | - | - |
Gain on sale of member interest in Visa Europe Ltd. | |||||||||
- | - | - | 7,476 | - | - | - | - | - | - |
Realized loss (gain) on marketable securities | |||||||||
- | - | - | 543 | -54 | 0 | 586 | 0 | 5,379 | 336 |
Gain on proceeds from insurance | |||||||||
- | - | - | - | - | 571 | 0 | 0 | 2,637 | - |
Gain on sales of buildings | |||||||||
- | - | - | - | - | - | - | - | - | 675 |
Interest in the equity of investments | |||||||||
- | - | - | -362 | 1,699 | 1,282 | 1,968 | 1,157 | -57 | -1,865 |
(i) Stock-based compensation included in selling, general and administrative expenses | |||||||||
2,236 | 3,581 | 3,740 | 2,680 | 5,185 | 5,382 | 5,875 | 3,325 | 4,081 | 2,226 |
Other | |||||||||
1,765 | -7 | 679 | - | - | - | - | - | - | - |
Change in assets and liabilities: | |||||||||
Restricted cash and cash equivalents | |||||||||
- | - | - | 22,548 | 28,286 | 25,292 | 23,006 | 7,733 | 5,011 | - |
Trade accounts receivable | |||||||||
-7,594 | 6,668 | 17,972 | -616 | -640 | 1,363 | -17,606 | -8,728 | 24,974 | -28,636 |
Prepaid expenses, other current assets and other assets | |||||||||
-4,119 | 18,889 | 4,856 | -8,372 | -2,122 | 4,628 | -2,890 | 2,100 | 1,781 | 10,293 |
Trade accounts payable, accrued expenses, other current liabilities and other liabilities | |||||||||
-7,546 | 12,769 | 16,722 | -10,099 | -4,125 | -5,914 | -22,578 | 10,703 | 39,201 | -27,320 |
Customer deposits at IDT Financial Services Limited (Gibraltar-based bank) | |||||||||
59,077 | 14,660 | 18,980 | - | - | - | - | - | - | - |
Deferred revenue | |||||||||
-3,853 | -21,439 | -9,543 | - | - | - | - | - | - | - |
Customer deposits | |||||||||
- | - | - | 25,344 | 25,939 | 30,186 | 17,998 | 9,057 | 130 | -200 |
Income taxes payable | |||||||||
- | - | - | - | - | -29 | -576 | -4,721 | -1,430 | 1,904 |
Deferred revenue | |||||||||
- | - | - | 2,211 | -2,939 | 8,917 | 6,253 | 6,666 | 8,042 | 3,003 |
Net cash (used in) provided by operating activities | |||||||||
85,137 | 20,394 | 36,094 | 49,054 | 30,534 | - | - | - | - | - |
Investing activities | |||||||||
Net cash provided by operating activities | |||||||||
- | - | - | - | - | 45,721 | 57,196 | 34,523 | 50,449 | 39,345 |
Capital expenditures | |||||||||
18,681 | 20,567 | 22,949 | 18,370 | 28,556 | 17,021 | 14,537 | 10,830 | 13,300 | 8,163 |
Proceeds from redemption of investments | |||||||||
- | - | - | 634 | 119 | 1,038 | 114 | 3,169 | 2,446 | 2,762 |
Proceeds from sale of member interest in Visa Europe Ltd | |||||||||
- | - | - | 5,597 | 0 | 0 | - | - | - | - |
Deposit on purchase of leasehold interest in building | |||||||||
- | - | - | - | - | - | 950 | 0 | - | - |
Collection of notes receivable, net | |||||||||
- | - | - | - | - | - | -750 | 0 | 88 | - |
(Repayment) collection of notes receivable, net | |||||||||
- | - | - | - | - | - | - | - | - | -130 |
Cash used for purchase of investments | |||||||||
- | - | - | 2,002 | 125 | 175 | 1,219 | 0 | 3,015 | 400 |
Proceeds from sale of interest in Straight Path IP Group Holding, Inc. | |||||||||
- | 6,000 | - | - | - | - | - | - | - | - |
Purchase of IP interest from Straight Path Communications Inc. | |||||||||
- | -6,000 | - | 0 | - | - | - | - | - | - |
Proceeds from sale of interest in Fabrix Systems Ltd. | |||||||||
- | - | - | 9,557 | 59,678 | 0 | 0 | - | - | - |
Payments for acquisitions, net of cash acquired | |||||||||
5,526 | - | 1,827 | 0 | 0 | - | - | - | - | - |
Cash used for purchase of investments | |||||||||
1,000 | 53 | 9,438 | - | - | - | - | - | 5,263 | - |
Proceeds from redemptions of investments | |||||||||
1,000 | - | 15 | - | - | - | - | 3,300 | 2,258 | - |
Purchases of other intangibles | |||||||||
- | - | - | - | - | 250 | 93 | 0 | - | - |
Proceeds from sale of building | |||||||||
- | - | - | - | - | 250 | 0 | 0 | 100 | 5,270 |
Proceeds from insurance | |||||||||
- | - | - | - | - | 571 | - | 0 | 3,524 | 500 |
Increase in restricted cash and cash equivalents | |||||||||
- | - | - | - | - | - | - | - | - | -44,165 |
Purchases of debt securities and equity investments | |||||||||
7,276 | 22,523 | 53,402 | 46,909 | 52,360 | 20,658 | 11,414 | 0 | - | - |
Proceeds from maturities and sales of debt securities and redemptions of equity investments | |||||||||
5,312 | 41,502 | 47,996 | 35,011 | 24,126 | 17,323 | 1,712 | 0 | 5,731 | 4,618 |
Net cash used in investing activities | |||||||||
-26,171 | -1,641 | -39,605 | -16,482 | 2,882 | - | - | - | - | - |
Financing activities | |||||||||
Net cash used in investing activities | |||||||||
- | - | - | - | - | -18,922 | -25,637 | -4,361 | -7,607 | 48,882 |
Dividends paid | |||||||||
- | 13,941 | 17,874 | 17,358 | 47,594 | 13,635 | 17,123 | 15,014 | 15,178 | - |
Distributions to noncontrolling interests | |||||||||
1,520 | 1,040 | 1,482 | 1,834 | 2,050 | 1,888 | 2,245 | 1,580 | 2,010 | 1,939 |
Proceeds from sale of Class B common stock to Howard S. Jonas | |||||||||
13,272 | - | 24,930 | - | - | - | - | - | - | - |
Repayment of other liabilities. | |||||||||
654 | - | - | - | - | - | - | - | - | - |
Repayments of borrowings under revolving credit facility | |||||||||
3,000 | 22,320 | - | 6,353 | - | - | - | - | - | - |
Repayments of capital lease obligations | |||||||||
- | - | - | - | - | - | - | 1,781 | 4,821 | 5,955 |
Proceeds from borrowings under revolving credit facility | |||||||||
3,000 | 22,320 | - | 0 | - | 56,000 | 21,062 | 0 | - | - |
Sale of Class B common stock | |||||||||
- | - | - | - | - | - | - | - | - | 290 |
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas | |||||||||
- | - | 1,000 | 0 | 0 | - | - | - | - | - |
Proceeds from sale of member interests in CS Pharma Holdings, LLC | |||||||||
- | - | 1,250 | 8,750 | 0 | - | - | - | - | - |
Cash of Rafael deconsolidated as a result of spin-off | |||||||||
- | 9,287 | - | 6,381 | 0 | 0 | 15,000 | 104,243 | - | 9,775 |
Proceeds from sale of member interests in CS Pharma Holdings, LLC. | |||||||||
- | - | - | - | - | - | 154 | 133 | - | - |
Proceeds from investment in subsidiary | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Purchases of stock of subsidiary | |||||||||
- | - | - | - | - | 1,133 | 1,804 | - | - | - |
Proceeds from sale of Zedge equity prior to the spin-off | |||||||||
- | - | - | 374 | 0 | - | - | - | - | - |
Proceeds from exercise of stock options | |||||||||
- | - | 836 | 0 | 3,424 | 609 | 921 | 0 | 1,674 | 90 |
Repayment of note payable | |||||||||
- | - | - | - | 13,271 | 64,318 | 21,304 | 332 | 4,602 | 622 |
Purchase of Class B common stock from Howard S. Jonas | |||||||||
- | - | - | - | 7,500 | 0 | - | - | - | - |
Repurchases of Class B common stock from Howard S. Jonas | |||||||||
- | - | - | - | - | - | - | - | 7,499 | - |
Repurchases of Class B common stock | |||||||||
3,882 | 2,293 | 1,838 | 4,773 | 3,202 | 1,005 | 1,079 | 2,816 | 205 | 1,879 |
Net cash (used in) provided by financing activities | |||||||||
7,216 | -26,561 | 6,822 | -27,575 | -70,193 | - | - | - | - | - |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash and cash equivalents | |||||||||
-12,180 | -957 | 293 | - | - | - | - | - | - | - |
Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents | |||||||||
54,002 | -8,765 | 3,604 | - | - | - | - | - | - | - |
Net cash used in financing activities | |||||||||
- | - | - | - | - | -25,370 | -36,418 | -125,633 | -32,641 | -19,790 |
Net cash used in operating activities | |||||||||
- | - | - | - | - | - | -2,638 | -1,984 | 6,389 | 17,788 |
Net cash used in investing activities | |||||||||
- | - | - | - | - | - | -350 | 4,992 | -4,026 | 6,815 |
Net cash provided by financing activities | |||||||||
- | - | - | - | - | - | - | - | 8,472 | 4,929 |
Net cash used in discontinued operations | |||||||||
- | - | - | - | - | - | -2,988 | 3,008 | 10,835 | 29,532 |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
- | - | - | -5,821 | -6,685 | 794 | 1,241 | -2,335 | 1,512 | -598 |
Net decrease in cash and cash equivalents | |||||||||
- | - | - | -824 | -43,462 | 2,223 | -6,606 | -94,798 | 22,548 | 97,371 |
Cash payments made for interest | |||||||||
- | - | - | - | - | 743 | 1,286 | 3,621 | 5,008 | 4,822 |
Cash payments made for interest | |||||||||
186 | 94 | 288 | 345 | 745 | - | - | - | - | - |
Cash payments made for income taxes | |||||||||
46 | 192 | 576 | 779 | 320 | 1,115 | 483 | 1,049 | 4,235 | 4,898 |
Supplemental schedule of non-cash investing and financing activities | |||||||||
Howard S. Jonas' advance payment used for sale of Class B common stock | |||||||||
1,500 | - | - | - | - | - | - | - | - | - |
Net assets excluding cash and cash equivalents of Rafael deconsolidated as a result of spin-off | |||||||||
- | -105,632 | - | - | - | - | - | - | - | - |
Net assets excluding cash and cash equivalents of Rafael deconsolidated as a result of spin-off | |||||||||
- | -105,632 | - | -4,681 | 0 | 0 | - | - | - | 6,011 |
Reclassification of liability for member interests in CS Pharma Holdings, LLC | |||||||||
- | - | 8,750 | - | 0 | - | - | - | - | - |
Shares of Visa Inc. Series C preferred stock received from sale of member interest in Visa Europe Ltd. | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Shares of Visa Inc. Series C preferred stock received from sale of member interest in Visa Europe Ltd. | |||||||||
- | - | - | 1,580 | 0 | - | - | - | - | - |
Net liabilities excluding cash and cash equivalents of Fabrix Systems Ltd. sold | |||||||||
- | - | - | - | 14,333 | 0 | 0 | - | - | - |
Adjustment to liabilities in connection with the Straight Path Communications, Inc. spin-off | |||||||||
- | - | - | - | - | 1,624 | 0 | - | - | - |
Escrow account balances included in other current assets used to reduce notes payable | |||||||||
- | - | - | - | - | - | 1,976 | 0 | 0 | - |
Escrow account balances included in other current assets used to reduce notes payable | |||||||||
- | - | - | - | - | - | - | 0 | 0 | - |
Net liabilities excluding cash and cash equivalents of Straight Path Communications, Inc. deconsolidated as a result of spin-off | |||||||||
- | - | - | - | - | - | 1,341 | -18,803 | 0 | - |
Mortgage notes payable settled in connection with the sales of buildings | |||||||||
- | - | - | - | - | - | - | - | - | 8,837 |
Net assets excluding cash and cash equivalents of subsidiaries deconsolidated as a result of the Genie spin-off | |||||||||
- | -105,632 | - | -4,681 | 0 | - | - | - | - | 6,011 |